Our parent company, Hanlim Pharmaceutical, is a South Korean pharmaceutical company that researches, develops, and sells ophthalmic drugs and various prescription drugs.
We spun off from Hanlim Pharmaceutical in October 2022 to focus on the commercialization of specialized drug formulations, including ocular implants and microarray patches.
SANGMYUNG innovation Co., Ltd. provides therapeutic solutions for various ophthalmic diseases, including retinal and macular diseases, glaucoma, and ocular surface diseases, through ocular drug delivery technology.
SANGMYUNG innovation Co., Ltd. utilizes simple, effective, pain-free microarray patch (MAP) technology
for transdermal drug delivery targeting a variety of diseases, including osteoporosis, alopecia, obesity, and more.
SANGMYUNG innovation Co., Ltd. provides CDMO services based on drug delivery platform technologies such as Ocular implants and MAP.
